These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 8450901)

  • 1. [Experiences with high dosage immunoglobulin G in neuromuscular diseases].
    Schuchardt V; Hotz M; Hund E; Sun S; Heitmann R; Hacke W
    Nervenarzt; 1993 Feb; 64(2):98-103. PubMed ID: 8450901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunoglobulin therapy of neuromuscular diseases].
    Schuchardt V
    Nervenarzt; 1993 Feb; 64(2):91-7. PubMed ID: 8450900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with chronic inflammatory demyelinating polyneuropathy.
    Van Doorn PA
    Rev Neurol (Paris); 1996 May; 152(5):383-6. PubMed ID: 8881435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin.
    Choudhary PP; Hughes RA
    QJM; 1995 Jul; 88(7):493-502. PubMed ID: 7633875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of immune-mediated, dysimmune neuropathies.
    Finsterer J
    Acta Neurol Scand; 2005 Aug; 112(2):115-25. PubMed ID: 16008538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose intravenous immunoglobulin G treatment of myasthenia gravis.
    Ferrero B; Durelli L
    Neurol Sci; 2002 Apr; 23 Suppl 1():S9-24. PubMed ID: 12032583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of autoimmune neuromuscular diseases with high-dose intravenous immune globulin.
    Soueidan SA; Dalakas MC
    Pediatr Res; 1993 Jan; 33(1 Suppl):S95-100. PubMed ID: 8433882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study.
    Kaynar L; Altuntas F; Aydogdu I; Turgut B; Kocyigit I; Hacioglu SK; Ismailogullari S; Turgut N; Erkurt MA; Sari I; Oztekin M; Solmaz M; Eser B; Ersoy AO; Unal A; Cetin M
    Transfus Apher Sci; 2008 Apr; 38(2):109-15. PubMed ID: 18331814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of myasthenia gravis in childhood associated with chronic inflammatory demyelinating polyradiculoneuropathy.
    Kimura K; Nezu A; Kimura S; Otsuki N; Kobayashi T; Nomura Y; Segawa M
    Neuropediatrics; 1998 Apr; 29(2):108-12. PubMed ID: 9638666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy.
    Zinman LH; Sutton D; Ng E; Nwe P; Ngo M; Bril V
    Transfus Apher Sci; 2005 Nov; 33(3):317-24. PubMed ID: 16239123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of myasthenia gravis with intravenous immunoglobulin G (IVIG)].
    Lavrnić DB; Stojanović V; Marinković Z; Pavlović S; Vidaković A; Apostolski S
    Srp Arh Celok Lek; 1995; 123(5-6):146-8. PubMed ID: 17974459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone.
    Lopate G; Pestronk A; Al-Lozi M
    Arch Neurol; 2005 Feb; 62(2):249-54. PubMed ID: 15710853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mechanism of action of intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy.
    Brand A; Van Doorn PA; Rossi F; Kazatchkine MD; Vermeulen M
    Prog Clin Biol Res; 1990; 337():405-9. PubMed ID: 2353004
    [No Abstract]   [Full Text] [Related]  

  • 14. [High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy].
    Tomiyama M; Baba M; Matsunaga M; Takada H; Okushima T; Narita S; Takebe K
    No To Shinkei; 1992 Nov; 44(11):979-82. PubMed ID: 1296721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines.
    Dalakas MC
    Muscle Nerve; 1999 Nov; 22(11):1479-97. PubMed ID: 10514226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee.
    Donofrio PD; Berger A; Brannagan TH; Bromberg MB; Howard JF; Latov N; Quick A; Tandan R
    Muscle Nerve; 2009 Nov; 40(5):890-900. PubMed ID: 19768755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune mediated neuropathies--an update on therapeutic strategies.
    Czaplinski A; Steck AJ
    J Neurol; 2004 Feb; 251(2):127-37. PubMed ID: 14991345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of myasthenia gravis occurring in the period of remission of chronic inflammatory demyelinating polyradiculoneuropathy].
    Inatus A; Ohi T; Shioya K; Matsukura S
    Rinsho Shinkeigaku; 1992 Aug; 32(8):878-9. PubMed ID: 1490316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.
    Gorson KC; Natarajan N; Ropper AH; Weinstein R
    Muscle Nerve; 2007 Jan; 35(1):66-9. PubMed ID: 16967492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP.
    van Doorn PA; Kuitwaard K; Jacobs BC
    J Peripher Nerv Syst; 2011 Jun; 16 Suppl 1():38-40. PubMed ID: 21696496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.